This Article Full Text Full Text (PDF) All Versions of this Article: 93/4/1238    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Google Scholar Articles by Mogul, H. R. Articles by Southren, A. L. PubMed PubMed Citation Articles by Mogul, H. R. Articles by Southren, A. L. Related Collections Metabolism Neuroendocrinology and Pituitary Thyroid

Growth Hormone Treatment of Adults with Prader-Willi Syndrome and Growth Hormone Deficiency Improves Lean Body Mass, Fractional Body Fat, and Serum Triiodothyronine without Glucose Impairment: Results from the United States Multicenter Trial

Departments of Medicine (H.R.M., A.L.S.) and Pediatrics (M.F.), New York Medical College, Valhalla, New York 10595; Department of Pediatrics (P.D.K.L., M.C.), David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095; Department of Pediatrics (B.Y.W., S.M.), St. Louis University, St. Louis, Missouri 63104; and Department of Pediatrics (W.B.Z., B.P.), Ohio State University, Columbus, Ohio 43210

Address all correspondence and requests for reprints to: Harriette R. Mogul, M.D., M.P.H., Division of Endocrinology, New York Medical College, 490 Munger Pavilion, Valhalla, New York 10595. E-mail: hrmogul{at}nymc.edu.

Context: GH replacement in Prader-Willi syndrome (PWS) children has well-defined benefits and risks and is used extensively worldwide. Its use in PWS adults has been limited by documentation of benefits and risks, as determined by larger multisite studies.

Objectives: Our objective was to evaluate the effectiveness and safety of GH in GH-deficient genotype-positive PWS adults.

Design: We conducted a 12-month open-label multicenter trial with 6-month dose-optimization and 6-month stable treatment periods.

Setting: The study was conducted at outpatient treatment facilities at four U.S. academic medical centers.

Patients: Lean and obese PWS adults with diverse cognitive skills, behavioral traits, and living arrangements were recruited from clinical populations.

Intervention: Human recombinant GH (Genotropin) was initiated at 0.2 mg/d with monthly 0.2-mg increments to a maximum 1.0 mg/d, as tolerated.

Main Outcomes Measures: Lean body mass and percent fat were measured by dual-energy x-ray absorptiometry.

Results: Lean body mass increased from 42.65 ± 2.25 (SE) to 45.47 ± 2.31 kg (P 0.0001), and percent fat decreased from 42.84 ± 1.12 to 39.95 ± 1.34% (P = 0.025) at a median final dose of 0.6 mg/d in 30 study subjects who completed 6–12 months of GH. Mean fasting glucose of 85.3 ± 3.4 mg/dl, hemoglobin A1c of 5.5 ± 0.2%, fasting insulin of 5.3 ± 0.6 µU/ml, area under the curve for insulin of 60.4 ± 7.5 µU/ml, and homeostasis model assessment of insulin resistance of 1.1 ± 0.2 were normal at baseline in 38 study initiators, including five diabetics, and remained in normal range. Total T₃ increased 26.7% from 127.0 ± 7.8 to 150.5 ± 7.8 ng/dl (P = 0.021) with normalization in all subjects, including six (20%) with baseline T₃ values at least 2 SD below the mean. Mildly progressive ankle edema was the most serious treatment-emergent adverse event (five patients).

Conclusions: This multicenter study demonstrates that GH improves body composition, normalizes T₃, and is well tolerated without glucose impairment in PWS genotype adults.